Mirador Capital Partners LP Buys Shares of 17,783 Astera Labs, Inc. $ALAB

Key Points

• Mirador Capital Partners LP has made a significant investment in Astera Labs, Inc., purchasing 17,783 shares valued at approximately $1.6 million during the second quarter.
• Astera Labs reported a strong earnings performance, with a revenue increase of 149.5% year-over-year, and earnings per share of $0.44, surpassing analysts' expectations.
• Insider selling activity has been notable, with CEO Jitendra Mohan selling over 91,000 shares for approximately $16.8 million, indicating a 4.04% decrease in his position.

Mirador Capital Partners LP acquired a new stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 17,783 shares of the company's stock, valued at approximately $1,608,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ALAB. Cetera Investment Advisers purchased a new position in Astera Labs in the 4th quarter valued at $460,000. Deutsche Bank AG boosted its position in shares of Astera Labs by 33.0% during the 4th quarter. Deutsche Bank AG now owns 7,695 shares of the company's stock worth $1,019,000 after purchasing an additional 1,909 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Astera Labs during the 4th quarter worth $2,395,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Astera Labs during the 4th quarter worth $1,543,000. Finally, Man Group plc purchased a new stake in shares of Astera Labs during the 4th quarter worth $8,231,000. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Astera Labs news, COO Sanjay Gajendra sold 280,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $170.02, for a total value of $47,605,600.00. Following the completion of the transaction, the chief operating officer owned 5,525,545 shares in the company, valued at $939,453,160.90. This represents a 4.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Truett Tate sold 100,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $171.38, for a total value of $17,138,000.00. Following the completion of the transaction, the chief financial officer owned 518,996 shares of the company's stock, valued at approximately $88,945,534.48. This represents a 16.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,576,713 shares of company stock worth $239,237,016 in the last 90 days. 12.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on ALAB shares. Susquehanna upped their price objective on shares of Astera Labs from $80.00 to $125.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Jefferies Financial Group upped their price objective on shares of Astera Labs from $95.00 to $130.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Morgan Stanley upped their price objective on shares of Astera Labs from $155.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, August 29th. Wall Street Zen raised shares of Astera Labs from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Finally, Citigroup upped their price objective on shares of Astera Labs from $160.00 to $275.00 and gave the company a "buy" rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $152.94.

Astera Labs Stock Performance

Shares of NASDAQ:ALAB traded down $6.68 during trading on Friday, reaching $245.20. 22,431,313 shares of the stock were exchanged, compared to its average volume of 4,617,677. The firm has a market cap of $40.76 billion, a price-to-earnings ratio of 437.86, a price-to-earnings-growth ratio of 6.39 and a beta of 1.48. Astera Labs, Inc. has a 12-month low of $47.00 and a 12-month high of $262.90. The firm's 50-day moving average price is $169.95 and its 200 day moving average price is $109.51.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.11. The firm had revenue of $191.93 million during the quarter, compared to analysts' expectations of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.Astera Labs's quarterly revenue was up 149.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, equities research analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current year.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.